
Oncology is a big investment target – here’s what investors care about
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.
Panel at MedCity CONVERGE discussed the practical applications of AI in the treatment of cancers.
We are looking for a select group of digital health startups to attend and present.